echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Make production easier and make tablets better

    Make production easier and make tablets better

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the process of R&D and production, we sometimes encounter some seemingly contradictory demands that are actually "just needed", such as requiring both high drug loading and small size of the tablet; both the tablet has sufficient hardness and the requirement for it.


    Performance analysis

    1.



    2.


    Test conditions: 500mg tablets 88% mannitol, 10% paracetamol (300μm particle size), 2% lubricant GP-8 rotary tablet machine test results are shown in Figure 2, Figure 3



    3.


    Test conditions: 500mg tablets 88% mannitol, 10% paracetamol (300μm particle size), 2% lubricant GP-8 rotary tablet machine test results are shown in Figure 4, Figure 5


    It can be seen from the test results that Mannogem ® XL Opal has the following advantages:

    ① It is a general excipient

    • High compressibility, high solubility, high hardness and low resilience

    ② Excellent disintegration performance, no disintegrant is needed
    • Disintegration speed increased by 20-30%

    ③ Lower ejection power
    • Less lubricant required-will increase hardness, disintegration properties and sensory feel

    • Conducive to scale-up and production

    Four, a broad formula design space

    Mannogem ® XL Opal can produce tablets that meet the hardness requirements in a large span of pressure range, with good production adaptability and easy replacement of equipment, thus having a broader space for formulation design


    Case analysis of paracetamol orally disintegrating tablets

    1.


    Test conditions:

    500mg tablets

    Drug = 300μm acetaminophen (poor compressibility)

    Prescription: 88% mannitol, 10% paracetamol API, 2% lubricant

    GP-8 Rotary Tablet Press


    test results:


    Use MannogemXL Opal's high-hardness ODT tablets with high API drug loading


    • XL Opal has superior high drug loading capacity

    • XL Opal has higher tensile strength and lower friability

    Under any API drug loading used in the experiment, the mannitol/starch co-processed ODT formulation did not reach the target friability


    2.


    Test conditions:

    500mg tablets

    Group 1: Co-processing of mannitol starch (10-78% mannitol content), 10% acetaminophen (particle size 300μm), 10% MCC, 2% lubricant;

    Group 2: 10-88% mannitol XL Opal, 10% paracetamol, 2% lubricant;

    GP-8 Rotary Tablet Press

    The test results are shown in Figure 8 and Figure 9




    Mannogem ® XL Opal can provide tablet formulations with sufficient hardness without the support of other auxiliary materials; competing products need to add 10% MCC to the formulation to meet the tablet requirements; competing products cannot achieve the target friability and hardness
    .


    3.
    Formula of acetaminophen orally disintegrating tablets

    Test conditions:

    500mg tablets

    Drug = 300μm acetaminophen (poor compressibility)

    86% mannitol, 10% acetaminophen API, 2% crospovidone, 2% lubricant

    GP-8 Rotary Tablet Press


    test results:





    From the above test results, it can be seen that Mannogem ® XL Opal can be used to prepare preparations that meet the requirements of orally disintegrating tablets; the preparations using competing mannitol-starch co-processed products have failed due to capping problems
    .
    It can be seen that using XL Opal can shorten the development time and increase the success rate
    .

    Summarize


    Mannogem ® XL Opal has the same physical properties as the standard spray-dried mannitol used on the market, but the performance is enhanced
    .

    The superior performance of XL Opal is reflected in:

    ① Higher tensile strength

    ② Higher active ingredient carrying capacity

    ③ Shorten the development cycle and increase the production speed, and increase the success rate

    • Improve the yield of problem prescriptions-reduce capping and fragility related problems

    • Broad formula design space

    • Smaller stripping force can increase production capacity

    ④ Speed ​​up the development of ODT formula
    • Fewer auxiliary materials are needed to accelerate development at a lower cost

    • Shorten the disintegration time limit to reach the target disintegration time

    • No need for a lot of additional adhesive

    ④ Improve patient compliance

    • Faster disintegration, better patient compliance and sensory experience

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.